Skip to main content

stock

TARS · Tarsus Pharmaceuticals, Inc.

What Tarsus Pharmaceuticals, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live TARS price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on TARS.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
43,882,996 as of 2026-07-30 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-8.0%
Net
-7.6%

Returns

ROE
-13.3%
ROA
-7.5%

Health

Current ratio
3.2x
Debt/equity
0.2x

Deep value

NCAV
$297.58M
NCAV per share
$6.78
Price/NCAV
Locked
NNWC
$14.39M
NNWC per share
$0.33
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$173.91M—Gross profit: unreported by this company.-$19.91M-$18.55M
10-Q filed 2026-08-06
2026-03-31$162.05M—Gross profit: unreported by this company.-$6.12M-$6.97M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31$151.67M—Gross profit: unreported by this company.-$7.98M-$7.96M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30$118.70M—Gross profit: unreported by this company.-$14.53M-$12.59M
10-Q filed 2025-11-04
2025-06-30$102.66M—Gross profit: unreported by this company.-$22.18M-$20.34M
10-Q filed 2026-08-06
2025-03-31$78.33M—Gross profit: unreported by this company.-$26.28M-$25.12M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31$66.41M—Gross profit: unreported by this company.-$24.42M-$23.56M
DEF 14A filed 2026-04-28
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$48.12M—Gross profit: unreported by this company.-$25.16M-$23.42M
10-Q filed 2025-11-04
Assets
$611.14M
Equity
$346.73M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$451.36M-$70.97M-$66.00M-$22.31M
2024-12-31$182.95M-$120.57M-$116.00M-$84.59M
2023-12-31$17.45M-$143.16M-$136.00M-$119.00M
2022-12-31$25.82M-$62.71M-$62.09M-$49.54M
2021-12-31$57.03M-$12.16M-$13.83M$3.16M
2020-12-31$0-$27.00M-$26.81M-$21.59M
2019-12-31—-$4.30M-$4.67M-$3.85M
2018-12-31——-$1.32M—

Company filings

events

  • Acquisition or sale completed, Other event

    Acquisition or sale completedOther event
    Sep 108-K
  • Results

    Results
    Aug 68-K
  • Material agreement, Unregistered share sale, Other event

    Material agreementUnregistered share saleOther event
    Aug 68-K
  • Material agreement, Unregistered share sale, Other event

    Material agreementUnregistered share saleOther event
    Aug 68-K
  • Executive or director change

    Executive or director change
    Jul 138-K
  • Material agreement, Unregistered share sale, Other event

    Material agreementUnregistered share saleOther event
    Jul 88-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named TARS, and the market events around them.

Sign in to see this

Board

The TARS board could not be loaded.

Retry the TARS board

nakagai

Signals on TARS come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the TARS board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Tarsus Pharmaceuticals, Inc. (TARS): SEC filings, financials and insider trades · Nakagai